Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
08 January 2022 - 03:00AM
Edgar (US Regulatory)
UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE
ISSUER
PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF
1934
For the Month of January 2022
Commission File Number:
001-40241
LAVA Therapeutics
N.V.
(Translation of registrant’s name into
English)
Yalelaan
60
3584
CM Utrecht, the Netherlands
(Address of principal executive
office)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form
40-F:
⌧ Form
20-F ◻ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule
101(b)(1): ◻
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule
101(b)(7): ◻
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LAVA
Therapeutics N.V.
|
|
|
|
|
|
Date:
January 7, 2022
|
|
|
|
By:
|
|
/s/
Edward F. Smith
|
|
|
|
|
|
|
Name
|
:
|
Edward
F. Smith
|
|
|
|
|
|
|
Title:
|
|
Chief
Financial Officer
|
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Apr 2022 to May 2022
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From May 2021 to May 2022
